甲磺酸溴隐亭和瑞舒伐他汀钙引起肝损害1例的病例分析  

A Case of Hepatic Lesion Caused by Rosuvastatin Calcium and Bromocriptine Methanesulfonate

作　　者：朱孝芹[1] 陈瑞玲[2] 

机构地区：[1]承德医学院附属医院药剂科,河北承德067000 [2]首都医科大学附属北京天坛医院药剂科,北京100050

出　　处：《药品评价》2013年第16期33-35,共3页Drug Evaluation

摘　　要：本文介绍了一例药物引起肝损害的病例,临床药师协同医师对患者用药做出分析,及时停用可疑药物瑞舒伐他汀钙和甲磺酸溴隐亭,甲磺酸溴隐亭引起肝损害的病历罕有报道,应引起临床重视。药物性肝损害重在预防,应避免肝损害药物联用,注意个体化给药。监测肝功能,出现异常,及时停药,应用保肝药物。A case history of hepatic lesion caused by bromocriptine methanesulfonate and rosuvastatin calcium was analyzed in this article.The clinical pharmacist analyzed the medications of the patient with the doctor,and bromocriptine methanesulfonate and rosuvastatin calcium which could cause hepatic lesion were stopped in time.It was unusual for bromocriptine methanesulfonate to cause hepatic lesion which was worth paying attention to.We should focus on the prevention of drug induced hepatic lesion.Drugs causing hepatic lesion should be avoided to be used together.Individualize drug administration should be promoted.Suspected drugs must be stopped once the results of hepatic function appeared abnormal and liver-protective agents should be given.

关 键 词：甲磺酸溴隐亭 瑞舒伐他汀钙 肝损害 

分 类 号：R595.3[医药卫生—内科学]